Targeting hepatic glutaminase activity to ameliorate hyperglycemia

Journal: Nature Medicine

Published: 2018-03-26

DOI: 10.1038/nm.4514

Affiliations: 13

Authors: 15

Go to article
Institutions FC
Pfizer R&D Cambridge, MA, United States of America (USA) 0.26
Pfizer Worldwide Research & Development (WRD), United States of America (USA) 0.20
Lewis-Sigler Institute for Integrative Genomics (LSI), Princeton University, United States of America (USA) 0.17
Touchstone Diabetes Center, UT Southwestern Medical Center, United States of America (USA) 0.07
Department of Internal Medicine, UT Southwestern Medical Center, United States of America (USA) 0.07
Institute for Diabetes, Obesity and Metabolism (IDOM), Penn, United States of America (USA) 0.06
Department of Cell and Developmental Biology, Penn, United States of America (USA) 0.06
Department of Physiology, Penn, United States of America (USA) 0.03
Department of Chemical and Biological Engineering, Princeton University, United States of America (USA) 0.03
Institute of Biomedical Sciences (ICBM), University of Chile, Chile 0.02
FONDAP Geroscience Center for Brain Health and Metabolism (GERO), Chile 0.02
Buck Institute for Research on Aging, United States of America (USA) 0.02
Department of Chemistry and Biochemistry, UCSB, United States of America (USA) 0.02

Return